Terms: = Uterine cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Diagnosis
91 results:
1. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
[TBL] [Abstract] [Full Text] [Related]
2. Assessing the Genomic Landscape of Cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
3. Clinically Aggressive uterine Epithelioid Leiomyosarcoma with Rhabdomyoblastic Differentiation and High Proliferation Rate: A Case Report.
Kim JY; Kim B
Am J Case Rep; 2023 May; 24():e939349. PubMed ID: 37190674
[TBL] [Abstract] [Full Text] [Related]
4. The statuses of her2 expression and mismatch repair in endometrial clear cell carcinoma.
Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
[TBL] [Abstract] [Full Text] [Related]
5. The role of her2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL; Banet N; Buza N
Pathology; 2023 Feb; 55(1):8-18. PubMed ID: 36503635
[TBL] [Abstract] [Full Text] [Related]
6. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract] [Full Text] [Related]
7. Microsatellite Instability-High Endometrial cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
[TBL] [Abstract] [Full Text] [Related]
8. Significance of her2 and VEGFR2 in Early-stage Endometrial cancer.
An HJ; Song DH; Kim YM; Jo HC; Baek JC; Park JE
In Vivo; 2022; 36(2):723-730. PubMed ID: 35241527
[TBL] [Abstract] [Full Text] [Related]
9. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
Kashofer K; Regauer S; Reich O; Petru E; Winter E
Gynecol Oncol; 2022 Apr; 165(1):121-128. PubMed ID: 35101299
[TBL] [Abstract] [Full Text] [Related]
10. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
11. her2 Expression in Endometrial cancers Diagnosed as Clear Cell Carcinoma.
Cagaanan A; Stelter B; Vu N; Rhode EN; Stewart T; Hui P; Buza N; Al-Niaimi A; Flynn C; Weisman PS; McGregor SM
Int J Gynecol Pathol; 2022 Mar; 41(2):132-141. PubMed ID: 33782344
[TBL] [Abstract] [Full Text] [Related]
12. Yolk Sac Tumor Arising in uterine Carcinosarcoma With Endometrioid and Serous Components: A Case Report With Immunohistochemical Analysis.
Grindstaff S; Hanley LC; Banet N
Int J Gynecol Pathol; 2022 Jan; 41(1):40-44. PubMed ID: 33770060
[TBL] [Abstract] [Full Text] [Related]
13. The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.
da Costa LT; Dos Anjos LG; Kagohara LT; Torrezan GT; De Paula CAA; Baracat EC; Carraro DM; Carvalho KC
Clinics (Sao Paulo); 2021; 76():e2324. PubMed ID: 33503190
[TBL] [Abstract] [Full Text] [Related]
14. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review.
Zeng XQ; Jiang SS; Peng YY; Liu MF; Ye CS; Dong JY
Chin Med Sci J; 2020 Dec; 35(4):377-382. PubMed ID: 33413755
[TBL] [Abstract] [Full Text] [Related]
15. Concordance Between Immunohistochemistry (IHC) and Silver Situ Hybridization (SISH) in Endometrial Carcinoma diagnosis: Using her-2/neu.
Mohammed Elmahi O; Ali Waggiallah H
Pak J Biol Sci; 2020 Jan; 23(10):1332-1337. PubMed ID: 32981267
[TBL] [Abstract] [Full Text] [Related]
16. Human epidermal growth factor receptor 2 fluorescence in situ hybridization and P57KIP2 immunohistochemistry using tissue microarray: Improving histopathological subtyping of hydatidiform mole.
López CL; Figueira Gouvêa AL; Rodrigues FR; Braga A; Valente Machado MD; Lopes VS
Placenta; 2020 Sep; 99():166-172. PubMed ID: 32810764
[TBL] [Abstract] [Full Text] [Related]
17. Relationship Between CIP2A and Endometrium cancer.
Aslan F; Güney G; Avcıkurt AS; Taşkın MI; Akgün GA
J Coll Physicians Surg Pak; 2020 Apr; 30(4):373-378. PubMed ID: 32513355
[TBL] [Abstract] [Full Text] [Related]
18. Role and significance of her-2/neu as a biomarker in the premalignant and malignant lesions of uterine cervix.
Varshney S; Maheshwari V; Aijaz M; Alam K
Ann Diagn Pathol; 2020 Apr; 45():151443. PubMed ID: 31923745
[TBL] [Abstract] [Full Text] [Related]
19. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract] [Full Text] [Related]
20. Ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.
Wang Z; Zhao D; Liu R; Zheng B
Medicine (Baltimore); 2019 Oct; 98(43):e17577. PubMed ID: 31651861
[TBL] [Abstract] [Full Text] [Related]
[Next]
